<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39179415</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1521-0103</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Aug</Month><Day>23</Day></PubDate></JournalIssue><Title>The Journal of pharmacology and experimental therapeutics</Title><ISOAbbreviation>J Pharmacol Exp Ther</ISOAbbreviation></Journal><ArticleTitle>KVX-053, a Protein Tyrosine Phosphatase 4A3 inhibitor, ameliorates SARS-CoV-2 Spike protein subunit 1 - induced acute lung injury in mice.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">JPET-AR-2024-002154</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1124/jpet.124.002154</ELocationID><Abstract><AbstractText>The Acute Respiratory Distress Syndrome (ARDS), often preceded by acute lung injury (ALI), is characterized by the accumulation of inflammatory fluid in the lung alveoli, leaky alveolar epithelium and endothelium, and overexpression of pro-inflammatory cytokines. This progression from ALI to ARDS is a major contributor to the high mortality observed in COVID-19 patients. The Spike protein of SARS-CoV-2 binds to lung ACE2 and, in addition to facilitating viral cell entry, it plays an important role in the development of ALI and ARDS, especially in the later phases of COVID-19 as well as long COVID. Protein tyrosine phosphatase (PTP) 4A3 is a key mediator of ARDS pathology. This study tested the hypothesis that targeting PTP4A3 would prevent COVID-19 associated ALI. Intratracheal administration of SARS-CoV-2 Spike protein Subunit 1 to K18-hACE2 transgenic mice expressing human ACE2 elicited pulmonary and systemic inflammation, leaky alveoli, overexpression of cytokines, structural lung injury and lung dysfunction; all these symptoms were ameliorated by the selective, allosteric inhibitor of PTP4A3, KVX-053. These findings provide the first evidence supporting a role for PTP4A3 in the development of SARS-CoV-2- mediated ALI. <b>Significance Statement</b> This study tested the hypothesis that targeting PTP4A3 would prevent COVID-19 associated ALI/ARDS. Intratracheal administration of SARS-CoV-2 Spike protein Subunit 1 to K18-hACE2 transgenic mice expressing human ACE2 elicited pulmonary and systemic inflammation, leaky alveoli, overexpression of cytokines and chemokines, structural lung injury and lung dysfunction; all these symptoms were ameliorated by the selective, allosteric inhibitor of PTP4A3, KVX-053. These findings suggest that this novel PTP4A3 inhibitor may be useful against COVID-19 and potentially other viral-induced ARDS.</AbstractText><CopyrightInformation>&#xa9; 2024 The Authors. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited and is not used for commercial purposes.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Solopov</LastName><ForeName>Pavel A</ForeName><Initials>PA</Initials><Identifier Source="ORCID">0000-0002-1705-027X</Identifier><AffiliationInfo><Affiliation>Old Dominion University, United States psolopov@odu.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colunga Biancatelli</LastName><ForeName>Ruben Manuel Luciano</ForeName><Initials>RML</Initials><Identifier Source="ORCID">0000-0002-1174-3876</Identifier><AffiliationInfo><Affiliation>Frank Reidy Reserach Center for Bioelectrics, Old Dominion University, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Day</LastName><ForeName>Tierney</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Frank Reidy Research Center for Bioelectrics, Old Dominion University, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gregory</LastName><ForeName>Betsy</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Frank Reidy Research Center for Bioelectrics, Old Dominion University, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharlow</LastName><ForeName>Elizabeth R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>Pharmacology, University of Virginia, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lazo</LastName><ForeName>John S</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0002-0645-4025</Identifier><AffiliationInfo><Affiliation>Pharmacology, University of Virginia, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Catravas</LastName><ForeName>John D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>OLD DOMINION UNIVERSITY, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R43 HL158409</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Pharmacol Exp Ther</MedlineTA><NlmUniqueID>0376362</NlmUniqueID><ISSNLinking>0022-3565</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Lung</Keyword><Keyword MajorTopicYN="N">pulmonary pharmacology</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>24</Day><Hour>16</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>24</Day><Hour>16</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>21</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39179415</ArticleId><ArticleId IdType="doi">10.1124/jpet.124.002154</ArticleId><ArticleId IdType="pii">jpet.124.002154</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>